Navigation Links
BioVex Announces Publication of Phase 2 Melanoma Results With OncoVEX (GM-CSF) in the Journal of Clinical Oncology
Date:11/2/2009

e and death," said Dr. Howard Kaufman of the Rush University Medical Center in Chicago, principal investigator of an ongoing Phase 3 OPTiM(TM) study with OncoVEX (GM-CSF) in Stage III and Stage IV melanoma. "The ability to simply administer the vaccine in the office setting represents a significant improvement in quality of life for patients with melanoma."

"We believe that OncoVEX (GM-CSF) is the most advanced clinical development program globally using viruses for cancer therapy, and we are committed to the further evaluation of OncoVEX (GM-CSF) for the treatment of metastatic melanoma and other solid tumors," said Robert Coffin, PhD, Founder & Chief Technology Officer of BioVex.

About the Phase 2 OncoVEX (GM-CSF) Study in Melanoma

The Phase 2 trial enrolled 50 patients with Stage IIIc (10 patients) and Stage IV melanoma (40 patients) who were treated with OncoVEX (GM-CSF) as a stand-alone therapy. The trial was designed to measure overall objective response, which is defined as a complete response, where disease is completely eliminated, or partial response, where there is a more than 30% reduction in disease burden. The vast majority of patients who entered the study had progressive disease after having failed conventional and experimental prior therapies. Fourteen objective systemic responses (28% objective response rate) were ultimately achieved, including on an extension protocol to which four patients were transferred having completed the main study, including 10 complete responses. Responses have been maintained for up to nearly four years so far. Responses were observed in patients with all stages of disease, including the complete resolution of un-injected visceral deposits.

About the OPTiM(TM) Phase 3 Study

BioVex has now begun a multi-national, randomized Phase 3 OPTiM Study to assess the efficacy and safety of treatment with OncoVEX (GM-CSF) as compared to subcut
'/>"/>

SOURCE BioVex Inc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. BioVex to Report Phase I/II Clinical Trial Results for the Front Line Treatment of Head and Neck Cancer With OncoVEX GM-CSF at the 2009 American Society of Clinical Oncology Meeting
2. BioVex Announces Regulatory Clearance to Commence a Clinical Study With ImmunoVEX HSV2; A Vaccine Candidate for Genital Herpes
3. BioVex Reports Positive Phase II Clinical Trial Results of OncoVEX GM-CSF in Metastatic Melanoma at the 2008 American Society of Clinical Oncology Meeting
4. BioVex to Report Phase II Clinical Trial Results of OncoVEX GM-CSF in Metastatic Melanoma at the 2008 American Society of Clinical Oncology Meeting
5. BioVex Agrees SPA With the FDA for a Pivotal Study With OncoVEX(GM-CSF) in Metastatic Melanoma and Announces Presentation of Phase II Results at ASCO
6. PDL BioPharma Announces Closing of $300,000,000 Securitization Transaction
7. Arcadia Resources Announces Webcast of Its Fiscal 2010 Second Quarter Conference Call
8. ATS Medical Announces First in World Human Robotic Endoscopic Aortic Valve Replacement
9. Nuevolution Announces Receipt of Milestone Payment From Merck & Co., Inc.
10. Stryker Announces Change in Chairman of the Board of Directors
11. Cardica Announces Fiscal 2010 First Quarter Financial Results and Business Progress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... YORK , May 27, 2015 The ... $416 billion in 2014 and with growth of 8% ... three categories out of pocket: directly on expenditures, co-pays ... drug purchases, and on premiums.  The publisher made its ... Expenditures in the United States ...
(Date:5/28/2015)... , May 28, 2015 A ... - Size, Industry Analysis, Trends, Opportunities, Growth and Forecast, ... $3.6 billion by 2020. The secondary syphilis testing would ... Latin America , Middle ... (LAMEA) market accounted for about 43% revenue share of ...
(Date:5/28/2015)... May 28, 2015  Service Strategies Corp., a ... that Fresenius Kabi, a global healthcare company that ... transfusion and clinical nutrition, has achieved certification under ... Standards for the seventh consecutive year. ... based upon a stringent set of performance criteria ...
Breaking Medicine Technology:Report: U.S. Out-of-Pocket Healthcare Spending Reaches $416 Billion 2Report: U.S. Out-of-Pocket Healthcare Spending Reaches $416 Billion 3Global Syphilis Testing Market is Expected to Reach $3.6 Billion, by 2020 - Allied Market Research 2Global Syphilis Testing Market is Expected to Reach $3.6 Billion, by 2020 - Allied Market Research 3Fresenius Kabi Recognized by Service Strategies Corp. for Technical Service Excellence 2Fresenius Kabi Recognized by Service Strategies Corp. for Technical Service Excellence 3
(Date:5/28/2015)... Boston Celtics Legend and Basketball Hall of ... Board of Directors members, will be hosting their 34th ... 4-7. For the past 34 years, the Havlicek’s have ... for children by bringing together friends, families, and celebrities ... Havlicek Celebrity Fishing Tournament will be held from June ...
(Date:5/28/2015)... Senior Housing Assistance Group (SHAG) proudly announces a ... Seattle Mariners team that won a record tying 116 ... digital advertising for SHAG to help promote their affordable ... communities slated to open in the next 2 to ... and University Place. , Filming of new commercials starring ...
(Date:5/28/2015)... CA (PRWEB) May 28, 2015 ... clinic will now be offering Echocardiography Examinations to ... be performed by renowned Qualified Medical Examiner and ... The echocardiography test is a non-invasive and cost-effective ... who are critically ill or have undergone surgery. ...
(Date:5/28/2015)... CompanionDx , a Houston-based ... it will present their integrated solution of next-generation ... annual American Society of Clinical Oncology (ASCO) in ... DNA in a patient’s tumor via a small ... changes or somatic mutations. Pharmacogenomics testing establishes a ...
(Date:5/28/2015)... Newton, Mass. (PRWEB) May 28, 2015 ... a $17.5 million round of financing led by ... health solutions company dedicated to transforming health care by ... nation’s largest and most utilized network for exchanging medical ... its growing customer base, increase the breadth of its ...
Breaking Medicine News(10 mins):Health News:The Genesis Foundation Prepares for Their Final Annual John Havlicek Celebrity Fishing Tournament 2Health News:SHAG Announces New Spokesperson: Lou Piniella 2Health News:Healthpointe Is Now Offering Echocardiography Examinations at the Anaheim Clinic. 2Health News:CompanionDx® Launches Integrated Genomic Solution at ASCO Meeting 2Health News:Cambia Health Solutions Leads New Round of Investment in lifeIMAGE 2Health News:Cambia Health Solutions Leads New Round of Investment in lifeIMAGE 3Health News:Cambia Health Solutions Leads New Round of Investment in lifeIMAGE 4
... Rigel,Pharmaceuticals, Inc. (Nasdaq: RIGL ) today ... R788, a novel, oral Syk kinase inhibitor, in ... study showed that R788 (tamatinib fosdium) can improve,platelet ... body attacks and,destroys its own blood platelets. ...
... health assistance in disaster zones is to be presented ... Dr Johan von Schreeb shows that international assistance is ... assessment having been made of the affected population. ... in a number of disaster situations. He examined the ...
... disease, but most remain unaware of it, hampering efforts ... transplant, according to a study funded by the National ... Journal of the American Medical Association. , ... of the U.S. population now have chronic kidney ...
... Corporation,(Amex: CVM ) announced today that its Board ... ensure that all of its stockholders,receive fair and equal ... of CEL-SCI. Geert Kersten, Chief Executive Officer, said ... stage for a cancer indication that has a,multi- billion ...
... the progression of chronic hepatitis C and advanced liver ... to eradicate the disease, a national study in which ... found. , Patients in the trial who were treated ... levels and liver inflammation, but the trial unequivocally demonstrated ...
... children , FRIDAY, Nov. 9 (HealthDay News) -- Certain ... according to studies presented this week at the American ... study found that abatacept, used to treat adults with ... treatment for children and adolescents with severe, treatment-resistant juvenile ...
Cached Medicine News:Health News:Rigel R788 Raises Platelet Counts in Immune Thrombocytopenic Purpura (ITP) Patients in Phase 2 Study 2Health News:Rigel R788 Raises Platelet Counts in Immune Thrombocytopenic Purpura (ITP) Patients in Phase 2 Study 3Health News:Rigel R788 Raises Platelet Counts in Immune Thrombocytopenic Purpura (ITP) Patients in Phase 2 Study 4Health News:Humanitarian assistance often lacks needs assessment 2Health News:Chronic kidney disease rises while most people with the condition remain unaware 2Health News:CEL-SCI Corporation Announces Adoption of Shareholder Rights Plan 2Health News:CEL-SCI Corporation Announces Adoption of Shareholder Rights Plan 3Health News:Interferon does not slow or stop hepatitis C from worsening, study finds 2Health News:Drugs Can Ease Juvenile Rheumatoid Arthritis 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: